Research programme: atopic dermatitis therapeutics - Palau Pharma
Alternative Names: UR-65318Latest Information Update: 16 Jul 2016
At a glance
- Originator Palau Pharma
- Class
- Mechanism of Action Histamine H4 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- Available For Licensing Yes
Highest Development Phases
- No development reported Atopic dermatitis
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Atopic-dermatitis in Europe
- 15 Sep 2010 UR 65318 is available for licensing. http://www.palaupharma.com
- 15 Sep 2010 Preclinical trials in Atopic dermatitis (unspecified route)